Tokyo, June 11, 2025 – BIC Medical, the women’s health division of BIC GROUP, is proud to announce that Rosi, a groundbreaking pain management device designed exclusively for women, has received official regulatory approval in Japan. This marks a significant milestone in women’s health, as Rosi introduces a new standard in comfort and effective pain relief for women.

Engineered with advanced technology and a discreet, body-conscious design, Rosi uses clinically backed TENS (Transcutaneous Electrical Nerve Stimulation) to target areas of discomfort with precision. The uniquely designed Butterfly Pad, shaped to match the contours of a woman’s body, delivers gentle, effective relief—making Rosi a trusted companion during the menstrual cycle and beyond.

“We are very happy to bring Rosi to the market,” said Indika Bandara, President of BIC GROUP. “Receiving regulatory approval in Japan affirms our commitment to safety, quality, and innovation. Rosi is more than a product—it’s a promise to support women’s comfort, confidence, and everyday well-being.”

The official launch of Rosi is scheduled for July 2025, with the exact date to be announced soon. Stay tuned for updates through our next press release and on social media @myrosicare.

For more information, visit rosicare.com or follow us on your preferred social platforms.

Media Contact
Natsuki N.
Promotions Specialist, BIC Medical
📧 contact@bicmedical.com
📞 +81-3-6269-9120